Novartis' Daniel Vasella - CEO Pay

Novartis' Daniel VasellaDaniel Vasella - Novartis

Total Compensation: $15.1M

Details: Vasella's contract was set to end in 2008. By the fall, he had promoted vaccines and diagnostics chief, Joerg Reinhardt, to be COO. Rumors began flying that--with Reinhardt tapped to be Vasella's sucessor--the CEO was on his way out the door. But Vasella said he loved coming to work and felt an "emotional connection" to Novartis and a "deep desire" for the company to succeed. The love must have been mutual because not only did Vasella receive a hefty 21 percent raise in his 2008 compensation over 2007, the company extended his contract. Considering the company had chopped his pay by 33 percent in 2007, it's safe to say there's some love in the air once again.

Novartis News:
Vasella could go ... but he'll probably stay
Novartis to cut reps, reassign execs
Abbott, Novartis post double-digit profit hikes
Vasella: 'Teva is better than we are'
Novartis buys Protez, invests in vaccines
Vasella shaking up Novartis ops

Novartis' Daniel Vasella - CEO Pay
Read more on

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.